logo

For the Inventor, By the Inventor

Boulder, CO, United States of America

Elizabeth A McFaddin

This inventor holds 16 USPTO granted patents and 2 published patent applications and 3 EPO patents, primarily in RET Kinase Inhibitors. Top assignees: Array Biopharma Inc., Eli Lilly and Company. Active years: 2018-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elizabeth A McFaddin. Retrieved from https://idiyas.com/inventor/elizabeth-a-mcfaddin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 100.0

 

Average Co-Inventor Count = 13.9

ph-index = 5

Forward Citations = 48(Granted Patents)


Location History:

  • Nederland, CO (US) (2023)
  • Boulder, CO (US) (2018 - 2024)

Company Filing History:

goldMedal13 out of 333 
 
Array Biopharma Inc.
 patents
silverMedal3 out of 4,522 
 
Eli Lilly and Company
 patents

Years Active: 2018-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
RET Kinase
Inhibitors
Pyrazolo Compounds
Pyrimidine Compounds
Crystalline Forms
Substituted Compounds
Pharmaceuticals
Cancer Treatment
Small Molecules
Drug Development
Chemical Compounds
16 patents (USPTO):Explore Patents
1. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),
2. 11697647 - RET kinase inhibitors (2023-07-11),
3. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),
4. 11613533 - Compounds useful for inhibiting RET kinase (2023-03-28),
5. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),
6. 11472802 - Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors (2022-10-18),
7. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),
8. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2021-01-05),
9. 10584124 - Crystalline forms (2020-03-10),
10. 10555944 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2020-02-11),
11. 10441581 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-10-15),
12. 10172851 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-01-08),
13. 10172845 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-01-08),
14. 10144734 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2018-12-04),
15. 10137124 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2018-11-27),

Title: The Innovative Contributions of Elizabeth A McFaddin

Introduction

Elizabeth A McFaddin is a prominent inventor based in Boulder, Colorado, known for her significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 16 patents, she has made strides in developing compounds that target critical health issues.

Latest Patents

Among her latest patents are the "Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors." These compounds are designed to inhibit RET kinase, which is crucial in treating and preventing diseases associated with RET, including various cancers. Another notable patent involves formulations containing these compounds, which are essential for developing effective treatments for RET-associated cancers.

Career Highlights

Throughout her career, Elizabeth has worked with leading companies in the pharmaceutical industry, including Array Biopharma Inc. and Eli Lilly and Company. Her work has focused on innovative solutions that address complex medical challenges, showcasing her expertise and dedication to advancing healthcare.

Collaborations

Elizabeth has collaborated with talented individuals in her field, including Gabrielle R Kolakowski and Julia Haas. These partnerships have contributed to her success and the development of groundbreaking therapies.

Conclusion

Elizabeth A McFaddin's innovative work in developing RET kinase inhibitors highlights her significant impact on the pharmaceutical industry. Her contributions continue to pave the way for advancements in treating critical health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…